- In an expansion of their partnership that began in 2013, BioMarin Pharmaceuticals (NASDAQ:BMRN) will use Myriad Genetics' (MYGN) myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian, and other cancers that may be sensitive to talazoparib. Financial terms are not disclosed.
-
Talazoparib is an investigational poly-ADP ribose polymerase (PARP) inhibitor being developed by BioMarin. PARP plays a key role in DNA repair by detecting and initiating repair if a DNA strand breaks. PARP inhibitors interfere with DNA repair in cancer cells so those with deficient DNA repair pathways, like those with BRCA mutations, are sensitive to PARP inhibitors which eventually leads to cell death.
- Myriad's myChoice HRD is a homologous recombination deficiency test that can detect when a tumor has lost its ability to repair breaks in double-stranded DNA, which makes it susceptible to PARP inhibitors and platinum drugs.